Fig. 7

MUC20 attenuates proteasome inhibitor resistance in MM by triggering cuproptosis via inhibiting MET/CDKN2A pathway in vivo. A Quantification of the volume of xenograft tumors derived from control, MUC20 OE, MUC20 OE + IGF-1R OE, and MUC20 OE + CDKN2A OE PI-resistant KAS-6/1 and U266 cells in the presence and absence of PI (CFZ), TTM or elesclomol. B Images of xenograft tumors formed in nude mice injected with control, MUC20 OE, MUC20 OE + IGF-1R OE, and MUC20 OE + CDKN2A OE PI-resistant KAS-6/1 and U266 cells in the presence and absence of PI (CFZ), TTM or elesclomol. C Quantification of the weight of xenograft tumors formed in nude mice injected with control, MUC20 OE, MUC20 OE + IGF-1R OE, and MUC20 OE + CDKN2A OE PI-resistant KAS-6/1 and U266 cells in the presence and absence of PI (CFZ), TTM or elesclomol. PR: proteasome inhibitor-resistant MM cells; OE: overexpression; TTM: tetrathiomolybdate. *P < 0.05, **P < 0.01, ***P < 0.001